RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
RVL Pharmaceuticals plc reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
RVL Pharmaceuticals plc reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, four executives at RVL Pharmaceuticals plc received on average a compensation package of $666K, a 27% decrease compared to previous year.
Average pay of disclosed executives at RVL Pharmaceuticals plc
Brian Markison, Chief Executive Officer, received $1.1M in total, which decreased by 10% compared to 2017. 57% of Markison's compensation, or $633K, was in salary. Markison also received $476K in non-equity incentive plan.
Tina deVries, EVP, Research & Development, received a compensation package of $551K, which decreased by 6% compared to previous year. 71% of the compensation package, or $393K, was in salary.
Andrew Einhorn, Chief Financial Officer, earned $505K in 2018.
James Schaub, Chief Operating Officer, received $498K in 2018.
Related executives
You may also like
Source: SEC filing on April 26, 2019.